Objective-The rate of rise oftotal plasma creatine kinase (CK) activity in the first 12 hours from presentation can be used to diagnose acute myocardial infarction. The aim of this study was to evaluate the performance of an abbreviated form of this test in the diagnosis of acute myocardial infarction in patients in whom the initial electrocardiogram was inconclusive. Methods-Using a protocol that requires only two CK measurements (separated by four hours) to estimate the rate ofrise, the performance of the test was investigated using data accrued from 345 consecutive admissions with suspected acute myocardial infarction. Results-A CK increment (ACK) of > 20% in the first four hours from presentation had a diagnostic sensitivity of 84.4% (95% confidence interval 75.5 to 93.3), specificity of 85.8% (80.1 to 91.5), positive predictive accuracy of 73.0% (62.9 to 83.1), and negative predictive accuracy of 92.4 % (87.9 to 96.9). Using more stringent diagnostic criteria (ACK > 20% and 4 h CK value > 160 U/litre) resulted in an increase in specificity and positive predictive accuracy to 96.5% and 91.1% respectively, and a small reduction in sensitivity and negative predictive accuracy to 79.7% and 91.3%, respectively. 94% of all infarcts were correctly identified using the ECG as the initial investigation and paired CK The presenting electrocardiogram (ECG) is a specific but relatively insensitive method for diagnosing acute myocardial infarction.'-3 In the presence of regional ST segment elevation, acute myocardial infarction can be diagnosed with a high degree of certainty. However, the presenting ECG is normal or inconclusive in a significant proportion of individuals with acute myocardial infarction, and additional testssuch as serial electrocardiography and biochemical assays which measure plasma markers of myocardial necrosis-are required to confirm or exclude the diagnosis. Typically, these investigations provide retrospective information up to 72 hours after the onset of symptoms. A simple accurate test, which is diagnostic soon after coronary occlusion and readily available around the clock, might guide the early management of patients with chest pain and allow clinical trials to be undertaken in which early therapeutic interventions in patients with biochemical evidence of acute myocardial infarction (but non-diagnostic ECGs) can be evaluated.
A D Hingorani, S O'Hanlon, S P Halloran, J P Wright, T H Foley Abstract Objective-The rate of rise oftotal plasma creatine kinase (CK) activity in the first 12 hours from presentation can be used to diagnose acute myocardial infarction. The aim of this study was to evaluate the performance of an abbreviated form of this test in the diagnosis of acute myocardial infarction in patients in whom the initial electrocardiogram was inconclusive. Methods-Using a protocol that requires only two CK measurements (separated by four hours) to estimate the rate ofrise, the performance of the test was investigated using data accrued from 345 consecutive admissions with suspected acute myocardial infarction. Results-A CK increment (ACK) of > 20% in the first four hours from presentation had a diagnostic sensitivity of 84.4% (95% confidence interval 75.5 to 93.3), specificity of 85.8% (80.1 to 91.5), positive predictive accuracy of 73.0% (62.9 to 83.1), and negative predictive accuracy of 92.4 % (87.9 to 96.9). Using more stringent diagnostic criteria (ACK > 20% and 4 h CK value > 160 U/litre) resulted in an increase in specificity and positive predictive accuracy to 96.5% and 91.1% respectively, and a small reduction in sensitivity and negative predictive accuracy to 79.7% and 91.3%, respectively. 94% of all infarcts were correctly identified using the ECG as the initial investigation and paired CK measurement as an additional test when this was inconclusive. In the 44 patients who received thrombolysis on the basis of an early biochemical diagnosis of acute myocardial infarction, the median time delay (75th centile) to thrombolysis was 10.75 (SD 15. The presenting electrocardiogram (ECG) is a specific but relatively insensitive method for diagnosing acute myocardial infarction.'-3 In the presence of regional ST segment elevation, acute myocardial infarction can be diagnosed with a high degree of certainty. However, the presenting ECG is normal or inconclusive in a significant proportion of individuals with acute myocardial infarction, and additional testssuch as serial electrocardiography and biochemical assays which measure plasma markers of myocardial necrosis-are required to confirm or exclude the diagnosis. Typically, these investigations provide retrospective information up to 72 hours after the onset of symptoms. A simple accurate test, which is diagnostic soon after coronary occlusion and readily available around the clock, might guide the early management of patients with chest pain and allow clinical trials to be undertaken in which early therapeutic interventions in patients with biochemical evidence of acute myocardial infarction (but non-diagnostic ECGs) can be evaluated.
Previous validation studies have shown that the rate of rise of total plasma creatine kinase (CK) activity in the first 12 Clinical details were obtained by review of the case notes. For patients with multiple admission episodes during the study period, details of the index presentation alone were recorded. The admission ECG was categorised as "diagnostic" of acute myocardial infarction if it showed regional ST elevation of 2 1 mm in two limb leads or 2 mm in two precordial leads. "Non-diagnostic" ECGs (the remainder) were categorised as "normal", "left bundle branch block", "ST depression", "T wave changes" (in the absence of other abnormalities), or "rhythm disturbances". The 96.9). The median (interquartile range) ACK Discussion was 203.0% (62.4 to 368.1) in the 64 patients In this study more than half (66%) of all with a final diagnosis of acute myocardial admissions with chest pain and suspected infarction and -7.5% (-15.6 to 4.3) in the 141 acute myocardial infarction had inconclusive subjects in whom infarction was excluded ECGs at presentation, which exceeds some (P < 0.0001).
previously published estimates. 1-3 10 The reason The data were re analysed using a CK4h value for this difference is not clear, but a lowering of > 160 U/litre as an additional criterion for a the threshold for hospital referral following the positive test result. This produced 51 TP, 5 FP, advent of thrombolytic treatment is one possi-136 TN, and 13 FN test results among the 205 ble explanation. These individuals represent a paired CK requests (table 3) . Sensitivity, large subset of admissions with chest pain and specificity, and positive and negative predictive many (36% in our study) will eventually be accuracy were 79.7% (69.8 to 89.6), 96.5% shown to have suffered an acute infarct, (93.5 to 99.5), 91.1% (83.6 to 98.5), and emphasising the relatively low sensitivity of the 91.3% (86. 8 as a more reliable guide to the performance of the test in the routine clinical setting. The CK increment was falsely positive in 20 subjects, of whom only one received thrombolysis. In 15 of the remaining 19 cases, absolute CK values were all < 160 U/litre (the upper limit of the normal range) and clinicians elected to disregard an increment > 20% unless one or both CK values were in excess of 160 U/litre. Previous studies have suggested that the specificity of the paired CK test can be increased by defining a positive test result as a CK increment of > 20% together with a four hour CK value in excess of the laboratory reference range.12 When we reanalysed the data using this definition, specificity and positive predictive values increased at the expense of a small reduction in sensitivity. There were 10 false negative paired CK tests; in seven of these both Oh and 4h CK values exceeded 160 U/litre, but ACK was < 20%. Five of these seven subjects presented more than 10 hours after the onset of pain and it is possible that in these individuals blood samples spanned the peak of the CK rise. The value of this protocol may thus be limited in subjects presenting many hours after the onset of chest pain.
While several major mortality trials have clearly shown the benefits of thrombolysis in patients presenting with ST elevation,"-5 it is uncertain whether the benefits of treatment outweigh the risks in patients with other ECG abnormalities (with the exception of left bundle branch block). The apparent failure of thrombolysis to influence the high mortality of subjects with ST depression'6 is surprising, but might be the result of a distinct pathological process operating in such patients, for example ongoing endogenous fibrinolysis and coronary recanalisation. However, since such patients have been relatively poorly represented in the major outcome studies, the failure to detect an influence of treatment may reflect diminished statistical power in the analysis of subgroups. A recent meta-analysis, which included five trials where the eligibility for thrombolysis was not dependent upon ECG changes, was unable to resolve this issue."7 Although the TIMI-IIIB trial failed to show any benefit for thrombolysis (in the form of alteplase) over and above standard anti-ischaemic and anticoagulant treatment in patients with unstable angina or non-Q wave myocardial infarction, the mortality in the placebo group in this study was low (2-3%) and the dose of alteplase used may have been suboptimal. '8 In accordance with these findings, however, present guidelines suggest that thrombolytic treatment should be reserved for patients presenting with chest pain and ST segment elevation or left bundle branch block.19 To date, many of the major trials have excluded subjects without diagnostic ECG changes of infarction. Those trials with less stringent entry criteria have still not used biochemical markers to confirm acute myocardial infarction before intervention in patients in whom the ECG is non-diagnostic. Further studies are thus required to determine whether outcome can be modified by targeted revascularisation (using thrombolytics or other agents) in those patients with very early biochemical evidence of infarction.
In our study, the decision to use thrombolysis was left to individual clinicians. As a result, 44 patients were given thrombolysis on the basis of a CK increment and these subjects provide useful data on the diagnostic delay introduced by a protocol requiring serial blood sampling. The median (75th centile) delay from symptom onset to thrombolysis in this group was 10.75 (SD 15.0) hours compared to 4.0 (6.75) hours in the 103 patients who received thrombolysis on the basis of the admission ECG. However, only two CK measurements are required with the strategy described and, with the appropriately equipped service, it should be possible to reduce the in-hospital diagnostic delay to approximately 4.5 hours. Provided that emergency call to arrival times can be reduced (in accordance with recent guidelines),'9 the delay from symptom onset to biochemical diagnosis in subjects with inconclusive ECGs might be of the order of six hours, allowing early management decisions based upon the result.
Other early biochemical markers of myocardial necrosis exist (including CK mass, CK-MB isoenzyme, troponin C, troponin T, and myoglobin), but few of the newer markers have been evaluated in the context of serial measurements.
1 2121 The performance of single measurements is markedly dependent on time after the onset of symptoms, and receiveroperator characteristics dictate that the diagnostic blood sample for these assays be obtained some time (up to six hours or more) after the onset of symptoms. The delay associated with serial CK measurements thus compares favourably with the existing alternatives. Further studies are required to determine whether the delays introduced by serial measurements can be reduced by the use of chemical reagent strips,14 or by the use of a shorter sampling interval facilitated by the use of a log CK activity/time nomogram. 6 The ECG remains the most rapid, convenient, and specific test for acute myocardial infarction.2' Biochemical tests should be viewed as an adjunct to-rather than a replacement for-the ECG, and the performance of biochemical assays is most appropriately assessed in those patients in whom the ECG is inconclusive. We have shown that paired, sequential creatine kinase measurement can be implemented round the clock in the acute clinical setting and that the analysis (even by wet chemistry methods) can be rapid enough to allow treatments based upon the result to be given within 12 hours of the onset of symptoms in most cases. A large number of additional infarcts can be identified early after the onset of chest pain using this strategy. Furthermore, in the presence of both a negative ECG and a negative CK test, acute myocardial infarction can be excluded with a high degree of certainty. The best use for such information in the clinical situation has yet to be defined. It may help in the allocation of resources such as coronary care beds and assist in prediction of future risk. 2627 The use of protocols of this type in controlled clinical trials might allow the role of therapeutic interventions in patients with early biochemical evidence of acute myocardial infarction but non-diagnostic ECGs to be more rigorously assessed. 
